Cortice Biosciences, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2014-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2018-01-31
- Lead Sponsor
- Cortice Biosciences, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT02047214
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States
🇺🇸Northwestern Medical Faculty Foundation, Chicago, Illinois, United States
Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2023-02-22
- Lead Sponsor
- Cortice Biosciences, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT01933815
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2007-11-06
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Cortice Biosciences, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT00553813
- Locations
- 🇺🇸
Desert Hematology Oncology Medical Group, Inc., Rancho Mirage,, California, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center - Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Center for Cancer and Blood Disorders, Bethesda, Maryland, United States
A Phase II Trial of TPI 287 in Patients With Metastatic Prostate Cancer
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Cortice Biosciences, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00479635
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Comprehensive Cancer Center at Desert Mountain, Palm Springs, California, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
- Conditions
- NeoplasmsHodgkin's DiseaseNon-Hodgkin's Lymphoma
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2007-10-15
- Lead Sponsor
- Cortice Biosciences, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT00256191
- Locations
- 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
- Prev
- 1
- 2
- Next